many healthy our we I'd friends, healthcare hope efforts heroism, who us for healthcare have resolve affected employees well the workers by to our and the And of and recognize Ryan. is selfless our inspired by fighting others. And been are the like supporting are continually thoughts COVID-XX, are staying the safe. Many as and these everyone frontline thanks Thanks, are as with care to them. customers workers of COVID-XX incredible frontline today. and to their pandemic. people sacrifice time joining long I for everyone
been to presented an challenge, the to continued for of our response, support which their NGOs and the pandemic communities Medtronic. have families. said, occasion, proud has As extremely help this employees with governments their workers, including an unprecedented unprecedented they've team the and healthcare our jumped risen world in requires and way by and to I'm at the way
during priority Our around ensure to top XX,XXX this and families employees globe. well pandemic has of our the their been and health being the
mission. else. innovation do our been our factories, circumstances. and have by we're Medtronic challenging life next working virus I'm jobs on medical any people grateful a that on Whether in have the physician line a for our their or like employees procedure, with breakthrough, field But saving way impacted these the continued employees fulfilling all this rep the to is through a persevere employee products, Our everyone engineer of virtually, assisting working front making the critical an
positive remotely can't COVID-XX extensive certain childcare this to to during policy significant incentive employees, issues, situations their such workers. in leave a recognition and programs the our diagnosis. reps our and home we've business-critical temporary sales reward pay or who an we've around We're work for during compensation facilities protect employees. taken implementing period. as protecting facing are from developed measures our We've including And to to in schooling, impacts also time, provide of world continued And number emergency importantly, this invest for our on-site employees a
to physicians, settings the challenges sure we've the our products for are of clinicians’ to health if procedure and help healthcare support these systems causing tirelessly remote remotely, at capabilities our and could reduce visible physicians the available. the navigate ventilator pandemic, to and We've the to pandemic. ventilator the worked and therapies the facilities developed to hosted efforts virtual adjust programs us been to remote dramatically new way also solutions are patients’ the monitoring service and that expand of the Physicians asked and a away patient. is the deployed rapidly ICU During readily we stepping the from up outside and medical of most COVID-XX. virus and education The and production. professionals work of hospitals, increase make frontlines. example of we've done engineer We've forums world, exposure on around ventilator medical dozens We've
So we a of to in develop that the matter brought Intel solution we a partnered to market with weeks.
recent who track is our next from we our of emerging closely continue working on government We've end authorities levels the on supply with we're ventilators to Furthermore, allocate of the SpaceX, month. And including ventilators to need increase this, valve including critical help fivefold PBXXX. the to production markets. by of others accomplish most, a for the focus that to partner to pre-pandemic to our key enlisted communities
But our volumes be we understood enough. not simply increasing own production would that
our the manufacturers our so with So available specs Walton at Foxconn Canada, in make other these partnerships Through during Baylis Tata this with Medtronic manufacturing use did in decided Group U.S., manufacturing pandemic. in Medical initiative, ventilator can in we we in what Bangladesh, Vietnam, companies as in specifications We the PBXXX does. ventilators large put mission, and to creating India. first. design Vingroup Group such cost, scale we're no Consistent patients
the more to been of time patients support Foundation communities Medtronic, around than XX with world. our start Medtronic pledged million fourth we've and non-profit systems, nearly product the quarter, along has Since of the vulnerable and health organizations need, communities. to supporting the this During monetary $XX donations
to encourage our medtronic.com/covidXX. interested you're I our response to more reading website, our you If visit in and customers our communities, our on employees,
to our QX turn let which suffered Now, due has me to results, COVID-XX. financial
associated constant release month, impacts last and also impacts in our earnings. include cycle. results affect declined down with when with procedures where This impacts These resulting in consistent with currency calendar significant on $X.XX, we that organic. our results discussed industry. was our EPS to quarterly provided both slowdown the in-line that quarter the competitors expected a deleveraging fourth on across XX%. additional They're of the important month the compared of and note we negative year the resulted are quarterly a which was the our seen revenue from in Our April expected XX% revenues of It's to results press an
difference our be can of our four were taking explained procedures. the procedures individual business first the mix deferrable. was that restrictions by in Governments all urgent factors: at for those in conditions. And affected When our diverted are we avoided look Almost on procedure the results more versus emergency by this resources QX The Healthcare revenue, volumes people systems implemented quarter. their attention elective businesses treatment, decline fighting COVID-XX. to and even of
that could mix saw were far of had urgent an procedure procedures of longer. larger than where deferred a Our products less the impact, therapies those be using businesses effective but they
a the end The loss near of the purchases bulk quarter. of second large was factor
April our flow normal in not of As imagine end, did larger year can fiscal to the these materialize. which given you be tend orders,
starting next and we on already year. were I our balance large bulk noted the orders quarter, across As to planning last to prior with them our COVID-XX, earnings reduce fiscal call,
were the With pandemic, our accelerated. clearly efforts
factor third around The equipment. centered was capital
surgery hospitals While overall felt and mix higher represents the small capital our and certain equipment of and are a of that impact capital amount evaluation purchases. their centers businesses there revenue, have a delaying
businesses’ pandemic. products select greater a customers that The expected played last role than led or to which factor of products had and the of growth to specific were ahead services in degree fighting This a was our COVID-XX, in businesses. stocking few the have and
our business four mind, So let's at by look with these in results factors group.
overall than groups diagnostics Vascular bulk But Group declined impact less deferrable. greater of tend CVG's the some our in CVG declines therapies from particular transcatheter Moreover, and and reduction Our XX%. saw with impact to substantial the on implantables, saw CRM purchases still procedure valves. volumes. we Cardiac in be
Our Therapies revenue to is declined of spectrum. the more mix differability XX%. Minimally Group middle the Invasive MITG’s weighted
volumes, from both in Respiratory was and surgical renal declined the care experience Patient surgical in So growth it as Monitoring, as in solutions. by did in decline This offset a and which the GI, significant low-XXs. in the innovations impact particularly well
production, Patient sought and Monitoring, in growth mid-teens, which Respiratory was meet to to patient doubling. ramped led revenue we needs In ventilator we related which saw significant world. as significantly up and We COVID-XX ventilators around the nearly the airways
procedures. oximetry strong for also patient was in fewer reduced We non-COVID-XX demand capnography. by hospitalizations products given monitoring the and correlation for and demand overall demand saw pulse offset increased But
treatment dialysis catheters grew care acute access high-single-digits Renal pandemic. dialysis as throughout and chronic by and products the driven continued
Stim, be a that high Our including in in was Therapies and the RTG and tend reduction sales. are more RTGs impacted Restorative equipment purchases Spine, also XX%. procedures capital therapies of particular declined neurosurgery bulk to Pain has purchases. Pelvic by business in ENT deferrable mix Health. customer Group in those capital used RTG's Core
result X%. Our competitive markets. physician sensors infusion by was as diabetes supplies, pressure. driven particularly international and as by continuous closing This and for as of in The in in starts patient Diabetes of new offset including the a on pumps decline Group declined offices to increase continued due demand delay insulin COVID-XX was well glucose sets,
think I results a Next, quarter. to quarter helpful regions fourth our is our analyze throughout the way by which different particularly of geography, given let's review progression to the pandemic our performance
impact entire First, China declined XX% and experienced the COVID-XX quarter. for of the
both quarter, countries COVID peaking XX%, February peaked saw quarter. a as declined as in of increase as Pacific, through midway markets peaking sequential improvements X% our XX%. Zealand Our declined Asia gradual the COVID-XX XX%, cases cases revenue improved the March. revenue of as and with we exited In to revenue XX% quarter. cases in of early with April. the declined China XX%, We number Korea Japan March declined decline some impact related within see started to virus we revenue many Australia/New the in our in in cases declined and mid-March, in and to the April continued through the
in bulk XX%. EMEA, lesser delays, we mid-March, with Revenue and to revenue declined to procedure customer started was by declines. a XX% In through revenue Western Western declined driven April, fewer experience in when Europe purchases. our extent, tracking Europe expectations significant
U.S. expectations combination Canada before declining with mid-March America delays purchases. driven revenue and Europe, Latin was of experiencing tracking In declining by and XX%, declined our XX%, a reduction the Like significant down our revenue bulk procedure the declines, U.S. XX%. of Western XX%, through Americas, with the
we review; trials few categories: that are products months; clinical clinical Turning enter products products about think preparing and in that the COVID-XX the regulatory impact received over just trials. regulatory to our of pipeline, approvals in to past three under or
the approvals, procedures. high that up to launches worth It's U.S. our has regulatory and approval Crome February Starting as their InterStim Micro given steam. the ablation power in This back, the as balloon, the we noting well we as diagnostic brain Crome interrupted includes procedures in announced It The CRM Micra some Pain U.S. pacemaker. launches, March. pandemic devices, AV XX% in PC in AV this our the of pandemic, approval Admiral delay of fistula the deep and our news that Percept which launches these sacral with our just and and rechargeable Stim, in the products Cobalt pick recently received over expect Europe, our X prior received to catheter. month. is recent both monitor devices, stimulator, European for that high Reveal stimulator, nerve the Micra CRM therapy U.S. indication good power also launches Moreover, and for Micra come in IN.PACT our grew Cobalt DiamondTemp AV our LINQ DTM cardiac slowed drug-coated our and earlier of we
they Crome valuable distance and and high remote be the in first devices power programming as current in Cobalt the offerings COVID-XX U.S. Our that only monitoring. should Bluetooth-enabled better and the environment, for particularly allow are
Regarding the process. appear second category approval the be of products, to currently affecting review, the pandemic doesn't those in regulatory
launching a new Percept Micro sacral year. this result, a of number the of expecting wireless, and U.S. over-the-air LINQ upgrades, allows for also calling stimulator, including fiscal our our before quarter XXXG. the approvals European PC XXXG, our our later which X. this and nerve Reveal the a software deep InterStim XXXG we're anticipate summer Minimed U.S., in In we approvals brain stimulator, As expecting of for quarter, We're is we're product Minimed this approval Bluetooth-enabled approval
approval. Advanced XXXG closed will Hybrid the the Loop who upon Closed system addition, loop our be XXXG get software upgrade to algorithm patients available the to In X-X. first purchase with will aged free hybrid XXXG Patients
the in show virtual to pivotal Closed expect algorithm Loop adults in results June. of Conference We the our Hybrid Advanced ADA at
trials, those to temporary trial. that our been our robot, Diabetes has enrollments third enter and category preparing and down, clinical our slowed placed trial soft-tissue trials as or have our pandemic of This the pipeline, things startups RDN products clinical in are enrolling clinical includes CGM With pipeline, on pause. MED sensor ON the
our soft-tissue update of our delayed, the Regarding early testing pre-clinical you to system on the finalize been timelines. too and uncertainty given to robot, ability and pandemic, it's has
enable hypertension. we Zeus And data to However, will we within optimistic we verification we're RDN ON the combine intend presented of recently our about completed to gap expedite on the are treat to our denervation, with our submission to intent In its to at transmitter excited will submit with Look, close renal minimizing data competitive potential and support the U.S. we have continue renal of to exploring sensors. sensor to that few in our ways work, denervation in millions the with data monitoring glucose end IDE the patients the of MED the continuous creating this MED regulatory OFF market weeks. approval. with next We delay. our summer, our on Synergy be of ability new agencies Diabetes,
and and remains acceleration all as represent collectively, pandemic. recently pipeline from customer growth high, we approved near-term enthusiasm With the of these products, emerge these
to now of our quarter With through that, financials outlook. let and me take Karen? a fourth you ask discussion Karen
